Potential OAI outcome at FTO-3 facility
FDA issued Form 483 with 10 observations at FTO-3; management has responded but risk of OAI classification could impact approvals and reputation.
DRREDDY / Q3-FY24 / risks
Keep the risk register visible.
Dr. Reddy's Laboratories · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
US generic price erosion
Price erosion in US generics continues, though management describes it as stable. Any acceleration could pressure margins.
Dependence on Revlimid for cash flows
Revlimid contribution remains meaningful; any unexpected decline could impact cash generation and ability to invest in pipeline.
Supply chain disruptions from Red Sea crisis
Geopolitical tensions are causing sea route disruptions; management is building inventory but costs could rise if situation persists.